Related Experiment Video
Updated: Jun 6, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Personalized nanovaccines for treating solid cancer metastases
Tang Feng1,2, Jia Hu1,3, Jirui Wen4
1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-the-art nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines.
Insights
Nanoparticle-delivered cancer vaccines show promise for treating cancer metastases by improving antigen presentation and tumor targeting. These nanovaccines aim to eradicate primary tumors and prevent or eliminate metastatic spread.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Cancer vaccines are explored for treating metastases, but clinical response rates are below 30%.
- Nanoparticles offer a platform to stabilize vaccines, enhance antigen recognition, and improve delivery to tumors and lymph nodes.
- Nanomedicines can potentially eradicate primary tumors and prevent or eliminate metastases.
Purpose of the Study:
- To review advanced nanocarriers for delivering cancer vaccines to metastases.
- To highlight properties of nanocarriers that improve anti-metastasis efficacy.
- To discuss combining nanovaccines with immunotherapy for metastatic cancer treatment.
Main Methods:
- Review of synthetic, semi-biogenic, and biogenic nanosystems for vaccine delivery.
- Analysis of physical and pharmacological properties influencing anti-metastasis effects.
- Examination of preclinical and clinical studies on nanovaccines and immunotherapy combinations.
Main Results:
- Nanoparticles enhance vaccine stability, antigen presentation, tumor penetration, and lymphatic drug distribution.
- Nanovaccines demonstrate potential in eradicating primary tumors and preventing/eliminating metastases.
- Combination strategies with immunotherapy target multiple steps in the metastatic cascade.
Conclusions:
- Nanocarriers represent a promising approach to improve cancer vaccine efficacy against metastases.
- Further research into nanovaccine properties and combination therapies is crucial.
- Addressing challenges in clinical translation is key for advancing cancer nanovaccines.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...